GlaxoSmithKline Pharmaceuticals Limited Sustainability Profile
GlaxoSmithKline Pharmaceuticals Limited, commonly known as GSK, is a leading global healthcare company headquartered in India. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK has since made significant strides in the pharmaceutical industry, focusing on research and development across various therapeutic areas, including vaccines, oncology, and respiratory health. With a strong presence in major operational regions such as Europe, North America, and Asia, GSK is renowned for its innovative core products, including vaccines like Shingrix and treatments for chronic diseases. The company’s commitment to scientific excellence and patient-centric solutions has solidified its market position, making it a trusted name in healthcare. GSK continues to achieve notable milestones, driving advancements that enhance global health outcomes.
DitchCarbon Score
How does GlaxoSmithKline Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline Pharmaceuticals Limited's score of 24 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GlaxoSmithKline Pharmaceuticals Limited's reported carbon emissions
In 2024, GlaxoSmithKline Pharmaceuticals Limited reported total carbon emissions of approximately 10,732,240 kg CO2e, comprising 774,320 kg CO2e from Scope 1 and 9,957,920 kg CO2e from Scope 2 emissions. This reflects a slight increase from 2023, where emissions totalled about 10,689,710 kg CO2e, with Scope 1 emissions at 486,950 kg CO2e and Scope 2 emissions at 10,202,750 kg CO2e. In 2022, the company recorded total emissions of around 10,994,650 kg CO2e, with Scope 1 at 286,210 kg CO2e and Scope 2 at 10,708,440 kg CO2e. GSK has not disclosed any specific reduction targets or initiatives as part of its climate commitments. The company has not reported any Scope 3 emissions, indicating a focus on direct and indirect emissions from its operations and energy use. The emissions intensity per rupee of turnover has been reported as approximately 7.13e-09 for 2024 and 7.29e-09 for 2023, adjusted for Purchasing Power Parity (PPP). Overall, GSK's emissions data reflects its ongoing operations without specific climate pledges or reduction targets currently in place.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 286,210 | 000,000 | 000,000 |
| Scope 2 | 10,708,440 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is GlaxoSmithKline Pharmaceuticals Limited's Industry?
How Carbon Intensive is GlaxoSmithKline Pharmaceuticals Limited's Location?
GlaxoSmithKline Pharmaceuticals Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GlaxoSmithKline Pharmaceuticals Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
